MX2022007163A - Uso de inhibidores de atr en combinacion con inhibidores de parp. - Google Patents
Uso de inhibidores de atr en combinacion con inhibidores de parp.Info
- Publication number
- MX2022007163A MX2022007163A MX2022007163A MX2022007163A MX2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A MX 2022007163 A MX2022007163 A MX 2022007163A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- inhibitors
- combination
- rnase
- atr
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title abstract 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 102000052609 BRCA2 Human genes 0.000 abstract 2
- 108700020462 BRCA2 Proteins 0.000 abstract 2
- 101150008921 Brca2 gene Proteins 0.000 abstract 2
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 abstract 2
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946876P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/064662 WO2021119523A1 (en) | 2019-12-11 | 2020-12-11 | Use of atr inhibitors in combination with parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007163A true MX2022007163A (es) | 2022-08-25 |
Family
ID=76316464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007163A MX2022007163A (es) | 2019-12-11 | 2020-12-11 | Uso de inhibidores de atr en combinacion con inhibidores de parp. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210177856A1 (https=) |
| EP (1) | EP4072551A4 (https=) |
| JP (1) | JP2023506787A (https=) |
| KR (1) | KR20220128350A (https=) |
| CN (1) | CN115103677A (https=) |
| AU (1) | AU2020402108A1 (https=) |
| BR (1) | BR112022011426A2 (https=) |
| CA (1) | CA3164203A1 (https=) |
| CL (1) | CL2022001540A1 (https=) |
| IL (1) | IL293810A (https=) |
| MX (1) | MX2022007163A (https=) |
| WO (1) | WO2021119523A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| BR112023024942A2 (pt) * | 2021-06-16 | 2024-02-15 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
| CN119212710A (zh) * | 2022-04-07 | 2024-12-27 | 修复治疗公司 | 使用atr抑制剂的方法 |
| US20250352539A1 (en) * | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024164089A1 (en) * | 2023-02-09 | 2024-08-15 | Repare Therapeutics Inc. | Use of atr inhibitors in the treatment of cancers with high tumor mutational burden |
| CN117159725B (zh) * | 2023-04-06 | 2024-07-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| EP4716756A1 (en) * | 2023-05-23 | 2026-04-01 | The Francis Crick Institute Limited | Targets for treatment of alt-positive cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2305221T3 (pl) * | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US11660301B2 (en) * | 2017-02-24 | 2023-05-30 | Bayer Pharma Aktiengesellschaft | Combination of ATR kinase inhibitors with PARP inhibitors |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-12-11 EP EP20898316.3A patent/EP4072551A4/en not_active Withdrawn
- 2020-12-11 AU AU2020402108A patent/AU2020402108A1/en not_active Abandoned
- 2020-12-11 KR KR1020227023568A patent/KR20220128350A/ko not_active Withdrawn
- 2020-12-11 US US17/119,512 patent/US20210177856A1/en not_active Abandoned
- 2020-12-11 WO PCT/US2020/064662 patent/WO2021119523A1/en not_active Ceased
- 2020-12-11 MX MX2022007163A patent/MX2022007163A/es unknown
- 2020-12-11 CA CA3164203A patent/CA3164203A1/en active Pending
- 2020-12-11 CN CN202080096191.XA patent/CN115103677A/zh active Pending
- 2020-12-11 BR BR112022011426A patent/BR112022011426A2/pt not_active IP Right Cessation
- 2020-12-11 JP JP2022535631A patent/JP2023506787A/ja active Pending
- 2020-12-11 IL IL293810A patent/IL293810A/en unknown
-
2022
- 2022-06-09 CL CL2022001540A patent/CL2022001540A1/es unknown
-
2023
- 2023-12-12 US US18/537,061 patent/US20240350505A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020402108A1 (en) | 2022-07-14 |
| WO2021119523A8 (en) | 2021-08-05 |
| EP4072551A4 (en) | 2023-11-15 |
| BR112022011426A2 (pt) | 2022-08-30 |
| IL293810A (en) | 2022-08-01 |
| KR20220128350A (ko) | 2022-09-20 |
| US20240350505A1 (en) | 2024-10-24 |
| CA3164203A1 (en) | 2021-06-17 |
| CL2022001540A1 (es) | 2023-01-13 |
| EP4072551A1 (en) | 2022-10-19 |
| CN115103677A (zh) | 2022-09-23 |
| WO2021119523A1 (en) | 2021-06-17 |
| JP2023506787A (ja) | 2023-02-20 |
| US20210177856A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007163A (es) | Uso de inhibidores de atr en combinacion con inhibidores de parp. | |
| BR112023024942A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer | |
| MY198308A (en) | Brm Targeting Compounds And Associated Methods Of Use | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| MX2022001328A (es) | Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia. | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| EP4253412A3 (en) | Inhibition of cytokine-induced sh2 protein in nk cells | |
| NZ748070A (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| MX2025012452A (es) | Métodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
| MY182650A (en) | Treatment of cancer with tor kinase inhibitors | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| PH12019550027A1 (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| WO2021002986A3 (en) | Bax inhibitors and uses thereof | |
| PH12022550244A1 (en) | Biomarkers for determining the efficacy of immune checkpoint inhibitors | |
| MX2019008545A (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| MX2023004847A (es) | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. | |
| MX2021013271A (es) | Inhibidores de la via rank en combinacion con inhibidores de cdk. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| WO2020055544A3 (en) | Method for treating pancreatic cancer |